Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt
Express News | Esperion Strengthens Balance Sheet With Closing of Significant Refinancing Transactions
Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4
Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8
Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target
12 Health Care Stocks Moving In Friday's Pre-Market Session
Noah sigma : How is that possible